







his case was was prepared by Pat Boonsom, under the supervision of Supawat Likittanawong, Adjunct Professor of Business Administration, BBA International Program, Thammasat Business School, Thammasat University for Thammasat Undergraduate Business Challenge 2021. Copyright © 2021 by Thammasat Undergraduate Business Challenge, Thammasat University

This case was written under the permission granted by the case company. This publication may not be digitized, photocopied, or otherwise reproduced, posted, or transmitted without permission of BBA International Program, Thammasat Business School, Thammasat University.

ทะบอนเลขที่ รับปัญ 2A71/26

(เมนทอล และ เมทิลซาลิไซเลต) สำหรับนักกีฬา

BOXIN

# Introduction

Provide a stride of the second string of the second string the second string of the second string of the second string of the second string of the second string s

Even though the pandemic has been challenging to deal with, it has allowed Namman Muay<sup>TM</sup> to get a clearer picture by elucidating the local market landscape. The insight obtained has prompted Namman Muay<sup>TM</sup> to review its domestic marketing strategy to cope with the near-term impact from COVID-19 and to achieve its aggressive growth target by 2023.



<sup>1</sup> See Appendix 4 for information on Lakeshore Capital.

## COVID-19 Overview

OVID-19 is a contagious disease that was first identified in Wuhan, China in December 2019. The virus has rapidly spread all over the world since then and, as a result, has been declared a pandemic by the World Health Organization on 11 March 2020. As of June 2021, there are over 180 million infections with over 4 million deaths around the world.<sup>2</sup> Thailand is no exception, with the third wave of infections that began in April 2021 still showing no sign of slowing down.

In an effort to control the outbreak, governments worldwide have taken a number of preventive and containment measures. In the early stages of the pandemic, citizens were advised to take personal preventive measures, such as social distancing, wearing face masks and practicing good hygiene. But as the pandemic spread, nations took more drastic measures, such as closing schools, cancelling mass gathering events, imposing strict travel restrictions and even lockdown of key cities and provinces.


Thailand had success in containing the outbreak in early 2020, but by the end of 2020, the nation was hit by another wave of COVID-19 that lasted a few months. The latest wave began in April 2021 and is still raging in June 2021, with thousands of new cases every day. Based on research by Krungsri Research, daily cases are expected to peak in August, then drop below 100 near the end of 2021. However, this will depend on how well the mass vaccination program progresses and whether new COVID variants will continue to emerge.




<sup>&</sup>lt;sup>2</sup> Source: World Health Organization, WHO Coronavirus (COVID-19) Dashboard, https://covid19.who.int/

### The third wave of COVID infection in Thailand tends to peak in Aug

Worst scenario has become our baseline as the number of new infections rises nearly 10,000 in early July. More importantly, Delta COVID variant cases are increasing noticeably and spreading to several provinces. Our forecast of this case is based on an assumption that infection in Thailand in coming months is mainly caused by Delta and Beta variants. So, historical infection data in Thailand, India, S.Africa, and UK is used for the projection. July lockdown is assumed to be 70% as effective as the Apr'20 lockdown. As a result, the new patient number tends to increase to 15,000 by early-Aug. 250k doses of COVID-19 vaccines per day are expected until the end of this year, making around 55mn doses would be taken by the end-21. This could help the number of new cases would decline, particularly after Sep. An efficacy of vaccines would remain a key factor to drive COVID cases down (assume 60% vaccine effectiveness). We expect to see the number of new patients below 1,000 in Nov this year. In the worst case, where vaccine is less effective and Jul lockdown cannot contain infection, the daily patient figure could rise above 20,000 and the lockdown might last longer.




### Assumption for each scenario and expected containment measures



Source: WHO, forecast by Krungsri Research

he pandemic has had an undeniable effect on the economy. The global GDP contracted by a record 3.6% in 2020, while the Thai GDP shrank by even more at 6.1%.<sup>3</sup> Such a large impact is partly due to Thailand's dependence on industries that were heavily affected by the pandemic. For example, the tourism industry, which contributed to over a fifth of Thailand's GDP in 2019, was devastated. Tourist arrivals fell to zero for several months after the incoming travel ban in March 2020 and in total decreased by more than 80% in that year.<sup>4</sup> The entertainment and sports industries also experienced a similar decline, as many venues were forced to close.



Consumption remains weak <u>as COVID-19 r</u>uns rampant.



Consumption remains weak as COVID-19 runs rampant. The latest wave of the pandemic has forced many public venues to remain closed, and places that reopened before are now closed again. Furthermore, the high uncertainty surrounding the pandemic clouds outlook for business and economic growth. Tourism also remains uncertain. Although there are steps taken to reopen the tourism industry, such as the Phuket Sandbox program, many obstacles delay recovery of the industry. According to Krungsri Research, tourist arrivals will only begin to see an increase in the last guarter of 2021. Even then, the projected foreign tourist arrivals of 280,000 in Q4 2021 is still far below pre-COVID-19 numbers. In fact, the Tourism Authority of Thailand does not expect the industry to fully recover until 2026.

<sup>3</sup> Source: World Bank, GDP growth (annual %), GDP growth (annual %) - Thailand

<sup>4</sup> Source: Ministry of Tourism and Sports, Tourism Statistics



### **COVID-19's Impact on The Thai Topical Analgesics Market**

he topical analgesics market in Thailand is severely impacted by COVID - 19. With the sharp reduction in tourist arrivals, the limitation of outdoor activities, the constraints on sports competitions and the economic impact on consumer spending, the demand for this product category has declined by over 50%. Topical analgesics are highly sought-after by Chinese tourists, who make up more than a quarter of all international tourists in Thailand. As a result, the near absence of tourists has had a detrimental effect on sales of many products. For example, Tiger Balm heat patch saw over 80% of its sales disappear with the absence of




tourists. Meanwhile, the various rounds of nationwide lockdowns and limitations on sporting events had led to the closure of numerous sports venues and an overall decrease of outdoor activities. This also reduced domestic consumption of topical analgesics. 6

# The Market Landscape

he pandemic affected different brands and product formats to varying degrees. For instance, the patch format, which is the most popular among tourists, saw its sales fall the most. Tiger Balm Medicated Plasters, which dominate the patch format market, witnessed a sharp decline in sales of almost 80% in 2020 versus 2019. On the other hand, product formats that mainly targeted the domestic market such as liniment were less affected. In the liniment format market, sales of Namman Muay<sup>™</sup> Liniment fell by only about 30%. The

impact on sales has also provided valuable insight into the composition of the customer base of both the overall market and Namman Muay<sup>™</sup>. For example, the sharp reduction in patch sales indicates that the majority of the patch market relies on tourists. Meanwhile, the reduction in sales of products targeted towards athletes like Namman Muav<sup>™</sup> indicates that about 30% of the Namman Muay<sup>™</sup> core market consists of athletes. This insight can be leveraged to guide Namman Muay<sup>™</sup>'s marketing efforts. Namman Muay<sup>™</sup> positions its liniment as a product for athletes, but blue-collar workers also contribute to a chunk of the sales. While the pandemic led to a decrease in overall physical activity, there is still demand for topical analgesics from customer including laborers, groups blue-collar workers, farmers, office workers as well as those who exercise at home.

#### Market Share by Format (in millions of baht)



Source: IMS<sup>5</sup>

Note: Numbers are illustrative and for purposes of case discussion only. Actual numbers might deviate from what is presented above.

<sup>&</sup>lt;sup>5</sup> IMS stands for Intercontinental Medical Statistics, a company that provides information, services and technology for the healthcare industry and is the largest vendor of physician prescribing data.

### **Company Research: Market Share of Top 10 Products in Each Format**<sup>\*</sup>

| LIQUID/OIL FORMAT | MARKET SHARE (in thousands of baht) |         |         |         |               |               |  |
|-------------------|-------------------------------------|---------|---------|---------|---------------|---------------|--|
| PRODUCT           | CORPORATION                         | 2018    | 2019    | 2020    | % GROWTH 2019 | % GROWTH 2020 |  |
| NAMMAN MUAY       | DEVAKAM OSOTH                       | 103,000 | 281,000 | 182,000 | 173%          | -35%          |  |
| AMMELTZ YOKO YOKO | KOBAYASHI                           | 105,000 | 114,000 | 71,000  | 9%            | -38%          |  |
| PERSKINDOL        | TRICHEMA AG                         | 85,000  | 81,000  | 40,000  | -5%           | -51%          |  |
| UNIREN            | UNISON                              | 58,000  | 64,000  | 64,000  | 10%           | 0%            |  |
| CASTLE SNAKE OIL  | WANG NGU COMPANY                    | 104,000 | 71,000  | 8,700   | -32%          | -88%          |  |
| PERSKINDOL COOL   | TRICHEMA AG                         | 51,000  | 54,000  | 23,000  | 6%            | -57%          |  |
| ELMETACIN         | MEDINOVA ( 2004 )                   | 38,000  | 34,000  | 22,000  | -11%          | -35%          |  |
| MARWIN            | BOONSONG OSOTH                      | 7,800   | 17,000  | 21,000  | 118%          | 24%           |  |
| REPARIL           | MADAUS                              | 8,100   | 10,000  | 5,800   | 23%           | -42%          |  |
| TIGER             | HAW PAR BROS INTER                  | 9,900   | 8,400   | 2,200   | -15%          | -74%          |  |
| OTHERS            |                                     | 37,200  | 30,600  | 23,300  | -18%          | -24%          |  |
| TOTAL             |                                     | 607,000 | 765,000 | 463,000 | 26%           | -39%          |  |




Oil & Liquid Format

| CREAM FORMAT        | MARKET SHARE (in thousands of baht) |         |         |         |               |               |  |
|---------------------|-------------------------------------|---------|---------|---------|---------------|---------------|--|
| PRODUCT             | CORPORATION                         | 2018    | 2019    | 2020    | % GROWTH 2019 | % GROWTH 2020 |  |
| COUNTERPAIN         | TAISHO PHARMACEUT                   | 441,000 | 319,000 | 187,000 | -28%          | -41%          |  |
| NECK&SHOULDER BOOST | HAW PAR BROS INTER                  | 166,000 | 118,000 | 24,000  | -29%          | -80%          |  |
| NECK&SHOULDER RUB   | HAW PAR BROS INTER                  | 85,000  | 72,000  | 13,000  | -15%          | -82%          |  |
| NEOTICA             | THAI NAKORN PATANA                  | 51,000  | 51,000  | 49,000  | 0%            | -4%           |  |
| NAMMAN MUAY         | DEVAKAM OSOTH                       | 7,300   | 47,000  | 29,000  | 544%          | -38%          |  |
| FLANIL              | BIOLAB                              | 28,000  | 27,000  | 26,000  | -4%           | -4%           |  |
| TIGER MUSCLE RUB    | HAW PAR BROS INTER                  | 23,000  | 18,000  | 3,800   | -22%          | -79%          |  |
| LONGANOID           | PRIMA HERB THAILAN                  | 4,600   | 15,000  | 18,000  | 226%          | 20%           |  |
| NEOTICA EX          | THAI NAKORN PATANA                  | 4,800   | 4,700   | 2,700   | -2%           | -43%          |  |
| PLAIVANA            | BANGKOK LAB                         | 2,600   | 4,400   | 3,700   | 69%           | -16%          |  |
| OTHERS              |                                     | 21,700  | 19,900  | 18,800  | -8%           | -6%           |  |
| TOTAL               |                                     | 835,000 | 696,000 | 375,000 | -17%          | -46%          |  |

|                    | 1                                   |               |               |           |               |               |  |
|--------------------|-------------------------------------|---------------|---------------|-----------|---------------|---------------|--|
| OINTMENT FORMAT    | MARKET SHARE (in thousands of baht) |               |               |           |               |               |  |
| PRODUCT            | CORPORATION                         | 2018          | 2019          | 2020      | % GROWTH 2019 | % GROWTH 2020 |  |
| PHOYOK HERBAL BALM | HERB THAI ZHONG                     | 581,000       | 294,000       | 30,000    | -49%          | -90%          |  |
| ZAMBUK             | BAYER CORP                          | 269,000       | 288,000       | 190,000   | 7%            | -34%          |  |
| TIGER BALM         | HAW PAR BROS INTER                  | 395,000       | 265,000       | 77,000    | -33%          | -71%          |  |
| GOLDEN CUP BALM    | THAUY THONG OSOTH                   | 236,000       | 239,000       | 227,000   | 1%            | -5%           |  |
| WHITE BALM         | MONKEY HOLD.P.B                     | 160,000       | 174,000       | 131,000   | 9%            | -25%          |  |
| WANGPROM GREEN     | WANGPROM HERBAL                     | 19,000        | 117,000       | 98,000    | 516%          | -16%          |  |
| PHOYOK HERB YELLOW | HERB THAI ZHONG                     | 80,000        | 39,000        | 4,100     | -51%          | -89%          |  |
| PHOYOK HERBAL WAX2 | PHOYOK HERB                         | 32,000        | 46,000        | 7,900     | 44%           | -83%          |  |
| WANGPROM YELLOW    | WANGPROM HERBAL                     | 4,400         | 12,000        | 27,000    | 173%          | 125%          |  |
| SIANG PURE CLASSIC | BERTRAM CHEMICAL                    | 11,000        | 6,300         | 1,600     | -43%          | -75%          |  |
| OTHERS             |                                     | 35,600        | 50,700        | 13,400    | 42%           | -74%          |  |
| TOTAL              |                                     | 1,823,000     | 1,531,000     | 807,000   | -16%          | -47%          |  |
| AN AND AND AND     | n had and out to had the            | Alter Charles | And the Class | BEAMARIES | - And         | PRANK STRATER |  |







**Ointment Format** 

| PATCH FORMAT       | MARKET SHARE (in thousands of baht) |           |           |         |               |               |  |
|--------------------|-------------------------------------|-----------|-----------|---------|---------------|---------------|--|
| PRODUCT            | CORPORATION                         | 2018      | 2019      | 2020    | % GROWTH 2019 | % GROWTH 2020 |  |
| TIGER MEDI.PLASTER | HAW PAR BROS INTER                  | 2,330,000 | 1,422,000 | 334,000 | -39%          | -77%          |  |
| TIGER BACK PAIN    | HAW PAR BROS INTER                  | 241,000   | 71,000    | 10,000  | -71%          | -86%          |  |
| SALONPAS           | HISAMITSU                           | 103,000   | 106,000   | 57,000  | 3%            | -46%          |  |
| NEOBUN             | NEOPLAST                            | 84,000    | 72,000    | 51,000  | -14%          | -29%          |  |
| NEOBUN GEL         | NEOPLAST                            | 26,000    | 52,000    | 25,000  | 100%          | -52%          |  |
| MENTOPAS           | NEOPLAST                            | 4,500     | 3,700     | 3,100   | -18%          | -16%          |  |
| TONPHOR ORANG BODY | DRAGON SKY (555)                    | 608       | 3,800     | 43      | 525%          | -99%          |  |
| TAIDA PLASTER      | HEALTH GREEN                        | 2,700     | 1,400     | 27      | -48%          | -98%          |  |
| POROUS CAPSICUM    | VORWERK&SOHN W.B                    | 1,500     | 1,500     | 1,100   | 0%            | -27%          |  |
| 8CROCODILES        | BC INTERLAB                         | 1,900     | 721       | 28      | -62%          | -96%          |  |
| OTHERS             |                                     | 1,792     | 879       | 702     | -51%          | -20%          |  |
| TOTAL              |                                     | 2,797,000 | 1,735,000 | 482,000 | -38%          | -72%          |  |

|                    |  | MARKET SHARE (in the  | MARKET SHARE (in thousands of baht)  |  |  |  |  |
|--------------------|--|---|--|--|--|--|--|
| CORPORATION        | 2018   | 2019  | 2020   | % GROWTH 2019  | % GROWTH 2020  |  |  |
| GLAXOSMITHKLINE    | 208,000  | 214,000   | 159,000  | 3%   | -26%   |  |  |
| TAISHO PHARMACEUT  | 205,000  | 175,000   | 108,000  | -15%   | -38%   |  |  |
| THAI NAKORN PATANA | 68,000   | 69,000  | 65,000   | 1%   | -6%  |  |  |
| TAISHO PHARMACEUT  | 71,000   | 50,000  | 19,000   | -30%   | -62%   |  |  |
| TRICHEMA AG        | 24,000   | 21,000  | 11,000   | -13%   | -48%   |  |  |
| PFIZER INTER. CORP | 14,000   | 10,000  | 8,100  | -29%   | -19%   |  |  |
| BRITISH DISPENSARY | 11,000   | 10,000  | 11,000   | - <b>9</b> %   | 10%  |  |  |
| A MENARINI         | 11,000   | 10,000  | 8,100  | -9%  | -19%   |  |  |
| BANGKOK LAB        | 9,200  | 8,300   | 7,400  | -10%   | -11%   |  |  |
| BANGKOK LAB        | 4,800  | 6,700   | 12,000   | 40%  | 79%  |  |  |
|                    | 74,000   | 75,000  | 55,400   | 1%   | -26%   |  |  |
|                    | 700,000  | 649,000   | 464,000  | -7%  | -29%   |  |  |
|                    | GLAXOSMITHKLINE<br>TAISHO PHARMACEUT<br>THAI NAKORN PATANA<br>TAISHO PHARMACEUT<br>TRICHEMA AG<br>PFIZER INTER. CORP<br>BRITISH DISPENSARY<br>A MENARINI<br>BANGKOK LAB<br>BANGKOK LAB | GLAXOSMITHKLINE208,000TAISHO PHARMACEUT205,000THAI NAKORN PATANA68,000TAISHO PHARMACEUT71,000TRICHEMA AG24,000PFIZER INTER. CORP14,000BRITISH DISPENSARY11,000A MENARINI111,000BANGKOK LAB9,200BANGKOK LAB4,80074,00014,000 | CORPORATION 2018 2019   GLAXOSMITHKLINE 208,000 214,000 1   TAISHO PHARMACEUT 205,000 175,000 1   THAI NAKORN PATANA 68,000 69,000 1   TAISHO PHARMACEUT 71,000 50,000 1   TRICHEMA AG 24,000 21,000 1   PFIZER INTER. CORP 14,000 10,000 1   BRITISH DISPENSARY 11,000 10,000 1   BANGKOK LAB 9,200 8,300 6,700   BANGKOK LAB 4,800 6,700 1   74,000 75,000 649,000 1 | CORPORATION 2018 2019 2020   GLAXOSMITHKLINE 208,000 214,000 1159,000   TAISHO PHARMACEUT 205,000 175,000 108,000   THAI NAKORN PATANA 68,000 69,000 65,000   TAISHO PHARMACEUT 71,000 50,000 19,000   TRICHEMA AG 24,000 21,000 11,000   PFIZER INTER. CORP 14,000 10,000 8,100   BRITISH DISPENSARY 11,000 10,000 8,100   BANGKOK LAB 9,200 8,300 7,400   BANGKOK LAB 4,800 6,700 12,000   T4,000 649,000 464,000 1464,000 | CORPORATION 2018 2019 2020 % GROWTH 2019   GLAXOSMITHKLINE 208,000 214,000 159,000 3%   TAISHO PHARMACEUT 205,000 175,000 108,000 -15%   THAI NAKORN PATANA 68,000 69,000 65,000 1%   TAISHO PHARMACEUT 71,000 69,000 65,000 1%   TAISHO PHARMACEUT 71,000 21,000 19,000 3%   TRICHEMA AG 24,000 21,000 11,000 -30%   PFIZER INTER. CORP 14,000 10,000 8,100 -29%   BRITISH DISPENSARY 11,000 10,000 8,100 -9%   BANGKOK LAB 9,200 8,300 7,400 -10%   BANGKOK LAB 4,800 6,700 12,000 40%   TAISHO PHARMANINI 74,000 75,000 55,400 1% |  |  |





Patch Format

### **Namman Muay** Current Marketing Focus

Based on marketing initiatives developed pre-COVID-19 pandemic, the brand had divided its potential customers into 5 core customer segments based on their age, occupation and level of physical activity, which is in line with typical segmentation for the analgesics market.



ENGER BY

тивс

#### Elderly

Their pain is caused by factors associated with aging, such as gradual bone and muscle mass loss, which leads to pain in the joints, feet and lower waist.

#### **Light Sports**

Their pain is caused by excessive use of their muscles when over-exercising. The pain often appears in the leg area (calf and thigh).

#### **Heavy Sports**

Their pain is similar to that of Light Sport's but with the addition of pains caused by accidents, which can lead to pain in any area of the body.

#### **Physical Labor**

Their pain stems from the overuse of muscles due to highly physically demanding work, which leads to pain in the arms, back, waist and legs.

#### **Office Syndrome**

Their pain is primarily caused by long hours of poor posture and commuting, which lead to pain in the neck and shoulders.

sers of topical analgesics can apply the medication in two ways: therapeutically and proactively. Therapeutic use is the application of analgesics after the pain is felt, while proactive use refers to the application of analgesics in advance to either prevent or reduce the severity of any anticipated pain and soreness. While any format can be used therapeutically and proactively, some formats are better suited than others depending on the use case, and therefore better serve certain segments. For instance, the spray format is often reserved for emergencies, such as severe pain from accidents.

Based on the above segmentation, Namman Muay<sup>™</sup>'s current market strategy is geared towards two key approaches. The first is its core blue - collar and sports segments that it is targeting with its liniment format. The second, which is currently a much smaller market for Namman Muay<sup>™</sup>, is the white - collar and elderly segments; for these segments, Namman Muay<sup>™</sup> is looking to penetrate the market with its cream and spray format.





# Case Question

o meet its ambitious domestic revenue target, Namman Muay<sup>™</sup> wants to relook at its domestic marketing strategy using its updated view of the market landscape. Management requires a near and medium-term marketing strategy for Namman Muay<sup>™</sup> that will help the brand achieve its domestic revenue target of 350 million baht by the end of 2023.

#### The strategy should clearly define:

- i) the segment that Namman Muay<sup>™</sup> should prioritize with clear rationale (this segment is not limited to the ones mentioned in this case)
- ii) what product (can be existing and/or new) Namman Muay<sup>™</sup> should offer to the prioritized segment, and how the product will be marketed (e.g., key marketing message, pricing, distribution channel(s)).

For background on Devakam Apothecary Hall, its history and businesses, please refer to Appendix 1.

#### Appendix 1. The Legacy of Devakam Osoth

In 1937 Major Sit Yotharak (Thongmuan Intharathat) a graduate of Siriraj Hospital, Thailand's first medical school, started a small pharmaceutical business. Over the next ten years, business flourished and eventually in 1946, Major Sit opened a clinic and formulated various kinds of drugs and household remedies. The first drug that was commercially launched was "Pra-sa-bor-rad", an aspirin based drug in powder form for fever and pain relief. This drug became quite popular as it was sweetened by Lactose and Saccharin sodium that made it easy to drink after dissolved in water (due to regulatory requirement, this product was later renamed as "Pra-sa-bor-rad"). Apart from "Pra-sa-bor-rad", the company also co-produced "Ga-Man" a sore throat lozenges and "Solex toothpaste" with Jumpathong Co., Ltd. As the drugs became more popular, Major Sit then decided to set up a limited company located nearby Dhevakam Rangrak Bridge on Nang Loeng Rd. in Bangkok, Thailand. The corporate brand "Devakam Apothecary Hall" was hence established with its name connected with its place of origin.

Later in 1957, Mr. Thongtos Intharathat, son of Major Sit, joined his father to run the family business. Mr. Thongtos was a businessman who was passionate about boxing. He set up his boxing gym called "Kingpetch" located on Petchburi road in Bangkok aimed at producing Thai boxers for both Muay Thai (Thai boxing) and western-style boxing. At that time, there were 3 main boxers at the gym, one of them was Mr. Mana Seedokbuab who was born in Hua Hin, Thailand. Mr. Mana was later given a ring name as "Pone Kingpetch". The name originated from Mr. Thongthos brother's name, Major Pone Intharathat, who passed away in 1949. Mr. Pone Kingpetch would later become a world famous boxer.

Back in those days, boxers would massage their muscles with stoke oil before training or a fight. Stoke oil has properties that help relieve muscle strains and stiffness. However, stoke oil was oily, pungent, and can cause eye irritation. Mr. Thongtos wanted to find a better alternative for his boxers and asked a pharmacist at the company to formulate an original composition that was a white opaque water-in-oil emulsion; the first version of Namman Muay<sup>™</sup> liniment oil was hence born. The product quickly became popular with boxers and eventually became the main product that was used by gym boxers. Namman Muay<sup>™</sup> not only helps relieve muscle strains and stiffness after the fights in place of stroke oil, but also helps boxers to warm up faster before boxing matches.

On 16th April 1960, Mr. Thongtos, as Pone Kingpetch's manager, led the boxer to defeat Pascual Pérez, an Argentine boxer, for the world flyweight championship. The late HM King Bhumibol Adulyadej (King Rama IX) was also in attendance to watch and witnessed the match at Lumpini Boxing Stadium in Bangkok. Although Pone Kingpetch won by split decision, it was

a historical match for Thailand. Pone Kingpetch became a legend in boxing overnight. Pone Kingpetch had become Thailand's first world boxing champion (Flyweight Division: 112 lbs.) with the support from his manager Mr. Thongtos and his trainer Mr. Niyom Thongchid, who were both behind his success. Since that victory day, April 16 was made "Thai Athlete's Day".

Apart from producing world-prized champions at Kingpetch gym, Namman Muay<sup>™</sup> liniment oil by Devakam Apothecary Hall has become a well-known product among boxing gym owners. Most of them bought and made sure that their Muay Thai and Western boxers applied Namman Muay<sup>™</sup> liniment oil, hoping that one of their fighters would become a world champion like Pone Kingpetch. As more and more boxers heard about Namman Muay<sup>™</sup>, demand grew. The company then developed the formulation of Namman Muay<sup>™</sup> to be more user-friendly and recognizable by changing the color from white opaque to yellow with an added unique scent. This scent is often cited by athletes to have a "motivational" effect and has been a recognizable trademark of the product since then. In 1962, the company was registered as a manufacturer and distributor of this unique product under the trade name "Namman Muay<sup>™</sup>.

Since then Namman Muay<sup>™</sup> has become a household name that is synonymous with muscle pain prevention and healing. It is so popular that the name Namman Muay<sup>™</sup> became a category name for topical analgesic in Thailand. Over the years, Namman Muay<sup>™</sup> has broadened its user base and is now widely-used not only among boxers but also by other athletes such as runners and football players as well as in the wellness and spas industry. Namman Muay<sup>™</sup> is also well received by the general public, and its application has gone beyond sports and is now a regular household remedy for muscle pain. In recent years, Namman Muay<sup>™</sup> has ventured abroad though on a limited scale through appointed distributors with key growth markets in Asia and Europe.

Namman Muay<sup>™</sup> comes in four different formats, with the liniment oil being the only format of the product up until the late 1980s, when the cream format was introduced and later followed by the spray format. The sponge format was launched in 2020, making it the newest. The liniment oil format is the dominant format for the Thai market, and the cream format is the main export format. Spray is still a relatively small portion of the overall sales because of limited market awareness. Due to being launched during the COVID-19 pandemic, the sponge format has had difficulty penetrating the market, so it is also a small portion of the overall sales.

To find out more about Namman Muay<sup>™</sup>, please visit https://nammanmuayofficial.com.

|                                | 2018A | 2019A | 2020A | 2021F | 2022F | 2023F |
|--------------------------------|-------|-------|-------|-------|-------|-------|
| Revenue - Domestic             | 175   | 260   | 180   | 180   | 270   | 350   |
| <b>Revenue - International</b> | 20    | 27    | 22    | 35    | 70    | 150   |
| Total Revenue                  | 195   | 287   | 202   | 215   | 340   | 500   |
| COGS                           | 100   | 130   | 95    | 95    | 145   | 215   |
| Gross Profit                   | 95    | 157   | 107   | 120   | 195   | 285   |
| Distribution Fee               | 0     | 20    | 12    | 15    | 25    | 35    |
| Selling expense                | 10    | 13    | 12    | 12    | 20    | 30    |
| A&P Expense                    | 20    | 45    | 25    | 30    | 50    | 80    |
| General Admin Expense          | 50    | 70    | 50    | 50    | 60    | 70    |
| Total SG&A                     | 80    | 148   | 99    | 107   | 155   | 215   |
| EBIT                           | 15    | 9     | 8     | 13    | 40    | 70    |
| Interest Expense               | 5     | 5     | 6     | 5     | 6     | 7     |
| EBT                            | 10    | 4     | 2     | 8     | 34    | 63    |
| Taxes                          | 0     | 0.8   | 0.4   | 1.6   | 6.8   | 12.6  |
| Net Profit                     | 10    | 3.2   | 1.6   | 6.4   | 27.2  | 50.4  |

#### Appendix 2. Devakam Apothecary Hall Income Statement (in THB Mn)

Source: DVK

Note: Numbers are illustrative and for purposes of case discussion only. Actual numbers might deviate from what is presented above.

#### Appendix 3. Devakam Osoth: 2018 to pre-COVID-19

Devakam Apothecary Hall remained a family business up until May 2018. Over the past 60 years, the company has grown through the capable hands of the family management team. However, growth began to plateau in late 2000 and became more a cash-cow type business for the family. At the same time, family members began to have varied interests outside the core business. Lakeshore Capital, a private equity fund, saw strong potential in the product and through discussions with the family was able to invest and became a major shareholder. Through this acquisition, Lakeshore Capital bought out a portion of the family shares and also injected new capital. Several family members remain onboard as members of the advisory board and shareholders, with almost all management positions replaced by a new team recruited from the industry.

Post-acquisition in June 2018, Lakeshore Capital recruited Ms. Aninthaya, an industry veteran with a strong track record, to head this new investment and became the chief executive officer of the company. Together with a team of new executives, Ms Aninthaya is tasked to lead the growth of DVK. Since then, Devakam Apothecary Hall and Namman Muay<sup>™</sup> has taken on a new life. Through many new initiatives that result in improved distribution, more focused marketing efforts and more refined pricing strategies, the team was able to deliver impressive growth with 2019 year-end forecast revenue closing expected to reach THB 305 Mil or 60% revenue growth from 2018. According to industry reports, Namman Muay<sup>™</sup> has also attained a much stronger market share ranking despite a fairly stagnant market growth. Its year on year ranking jumped from number 16 in 2018 to number 4 in 2019.

Through new distribution initiatives that open up new channels and outlets, Namman Muay<sup>™</sup> is now available in more than two thousand outlets nationwide. It can now be found not just in drug retail chains like Boots or Watsons but also in convenience stores like 7-11.

A new campaign is also in place to revitalize the brand with the launch of the first commercial in almost a decade. A famous Thai celebrity "Tono" Pakin Kumwilaisuk has been signed on as the presenter of Namman Muay<sup>™</sup> with the first television commercial to be aired in October 2019. This commercial is also geared at supporting the pricing adjustments made to the product in 2019. Overall the domestic market is looking to deliver on its ambitious growth targets.

Post-acquisition, several adjustments were made to the organization. A new organization structure was put in place with clearly defined roles; a new board was also formed with industry veterans who have extensive experiences appointed as independent directors and a new compensation structure was put in place to better align incentives and performance.

#### **Appendix 4. Introduction to Lakeshore Capital**

### LAKESHORE CAPITAL

Founded in 2009, Lakeshore Capital is a leading international private equity firm that focuses on growth businesses in Thailand and the Greater Mekong Sub-region. The firm provides expansion capital to industry-leading companies and works with management teams to grow their businesses. We create value by providing capital as well as business advice on strategy, finance, M&A, operational improvement, recruiting and international expansions.

Lakeshore Capital has a broad range of sectors of interest including, but not limited to, food, retail, consumer products, light manufacturing, healthcare, education, logistics and business outsourcing.

Our management team consists of experienced professionals with backgrounds in management consulting, investment banking, private equity and the corporate sector. We have a thorough understanding of local business practices, capital markets, culture and politics, combined with deep- rooted relationships with business leaders and investors.

Lakeshore Capital is a member of EMPEA (https://www.empea.org/), the global industry association for private capital in emerging markets.

Lakeshore Capital focuses on investing in the most attractive businesses, partnering with leading companies with strong competitive positions in their respective markets. Lakeshore is exploring investment opportunities across a broad range of industries. Priority, however, will be given to companies in food, retail, consumer products, light manufacturing, healthcare, education, logistics and business outsourcing. Thailand is the geographical focus area for investments but we also consider investment opportunities in the Greater Mekong Sub-region.


Lakeshore looks for companies with the following characteristics:

- Sustainable market leadership position with further growth potential;
- Strong operating cash flow and margin expansion potential;
- Strong, entrepreneurial management team with growth aspirations

For every investment, the maximization of value is driven by the ability to improve the fundamental business performance.


Lakeshore can assist companies at strategic, financial and operational levels by putting in place, where necessary, new sets of competencies and by driving growth at "just-below-board" level using our dedicated in-house consulting team. Lakeshore can also assist companies on M&A transactions to help accelerate growth as well as add human resource capacity to key functions by sourcing professionals through our extensive network of relationship across multiple industries and functions.

Source: Lakeshore Capital



#### Appendix 5. Thailand Age Structure


Appendix 6. Thailand Labour by Category



THAILAND LABOUR BY CATEGORY % OF TOTAL

Source: DVK

Note: Numbers are illustrative and for purposes of case discussion only. Actual numbers might deviate from what is presented above.



#### Appendix 7. Percentage of Sales by Channel

%Sales By Channel

Source: DVK

Note: Numbers are illustrative and for purposes of case discussion only. Actual numbers might deviate from what is presented above.

#### Challenge your limit, never miss an opportunity

Designed by: Apicha Apiwongthana







LAKESHORE CAPITAL





